Clinical baseline factors predict response to natalizumab: their usefulness in patient selection

BACKGROUND: Optimal patient selection would improve the risk-benefit ratio of natalizumab treatment for relapsing-remitting multiple sclerosis (RR MS). Clinical features of subjects responding to natalizumab have not been univocally recognized. METHODS: Longitudinal data on RR MS patients treated wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Laroni, Alice, Gandoglia, Ilaria, Solaro, Claudio, Ribizzi, Giuseppe, Tassinari, Tiziana, Pizzorno, Matteo, Parodi, Sergio, Baldassarre, Giovanna, Rilla, Maria Teresa, Venturi, Simonetta, Capello, Elisabetta, Sormani, Maria Pia, Uccelli, Antonio, Mancardi, Giovanni Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045962/
https://www.ncbi.nlm.nih.gov/pubmed/24885703
http://dx.doi.org/10.1186/1471-2377-14-103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4045962/
https://www.ncbi.nlm.nih.gov/pubmed/24885703
http://dx.doi.org/10.1186/1471-2377-14-103

Ejemplares similares